Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shixi Zhang

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Scientific Reports|February 26, 2026
Evaluating the effectiveness and safety of Azvudine for hospitalised patients with COVID-19 and hypertension: a multicenter retrospective cohort studyYu Chen, Huan Li, Yichen Ma, et al.
Frontiers in Cellular and Infection Microbiology|June 11, 2026
Development of a machine learning-based mortality prediction model for patients with mental disorders and COVID-19Yi Zhang, Haiyu Wang, Mengzhao Yang, et al.
Frontiers in Pharmacology|June 27, 2024
A phase I, randomized study to evaluate the safety, tolerability, and pharmacokinetics of mefunidone in healthy subjectsMai Han, Bishan Huo, Gaoyun Hu, et al.
BMC Infectious Diseases|February 25, 2025
Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort studyBenchen Rao, Daming Wang, Mengzhao Yang, et al.
Scientific Reports|March 31, 2025
Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19Bohan Jia, Junyi Sun, Di Zhu, et al.
Acta Pharmaceutica Sinica. B|May 15, 2025
A retrospective cohort study of the efficacy and safety of oral azvudine <i>versus</i> nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 yearsBo Yu, Haiyu Wang, Guangming Li, et al.
Iscience|February 25, 2025
Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetesGuanyue Su, Silin Li, Donghua Zhang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 22, 2025
The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS-CoV-2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort StudyJunyi Sun, Mengzhao Yang, Guanyue Su, et al.
Signal Transduction and Targeted Therapy|November 12, 2024
Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trialXuhua Duan, Hao Li, Donglin Kuang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 11, 2025
Effectiveness and Safety of Oral Azvudine for Elderly Hospitalized Patients With COVID-19: A Multicenter, Retrospective, Real-World StudyRanran Sun, Haiyu Wang, Junyi Sun, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Scientific Reports|February 26, 2026
Evaluating the effectiveness and safety of Azvudine for hospitalised patients with COVID-19 and hypertension: a multicenter retrospective cohort studyYu Chen, Huan Li, Yichen Ma, et al.
Frontiers in Cellular and Infection Microbiology|June 11, 2026
Development of a machine learning-based mortality prediction model for patients with mental disorders and COVID-19Yi Zhang, Haiyu Wang, Mengzhao Yang, et al.
Frontiers in Pharmacology|June 27, 2024
A phase I, randomized study to evaluate the safety, tolerability, and pharmacokinetics of mefunidone in healthy subjectsMai Han, Bishan Huo, Gaoyun Hu, et al.
BMC Infectious Diseases|February 25, 2025
Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort studyBenchen Rao, Daming Wang, Mengzhao Yang, et al.
Scientific Reports|March 31, 2025
Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19Bohan Jia, Junyi Sun, Di Zhu, et al.
Acta Pharmaceutica Sinica. B|May 15, 2025
A retrospective cohort study of the efficacy and safety of oral azvudine <i>versus</i> nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 yearsBo Yu, Haiyu Wang, Guangming Li, et al.
Iscience|February 25, 2025
Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetesGuanyue Su, Silin Li, Donghua Zhang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 22, 2025
The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS-CoV-2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort StudyJunyi Sun, Mengzhao Yang, Guanyue Su, et al.
Signal Transduction and Targeted Therapy|November 12, 2024
Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trialXuhua Duan, Hao Li, Donglin Kuang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 11, 2025
Effectiveness and Safety of Oral Azvudine for Elderly Hospitalized Patients With COVID-19: A Multicenter, Retrospective, Real-World StudyRanran Sun, Haiyu Wang, Junyi Sun, et al.
Pageof 6